---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004094"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:14:21.785452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB

## Summary
- Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.
- Arbutus now holds global rights to imdusiran; reports 8 patients achieved functional cure in Phase 2a trials IM-PROVE I/II to date.
- New Scientific Advisory Board formed with five HBV experts to advise on late-stage clinical development of cHBV pipeline.

## SEC filing metadata
- accession: 0001171843-25-004094
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/0001171843-25-004094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/f8k_062525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004094
- JSON: https://secwatch.observer/filing/0001171843-25-004094.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.